K.J. Harrison & Partners Inc Sells 1,010 Shares of Stryker Co. (NYSE:SYK)

K.J. Harrison & Partners Inc reduced its position in shares of Stryker Co. (NYSE:SYK) by 6.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,193 shares of the medical technology company’s stock after selling 1,010 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Stryker were worth $4,550,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Farmers & Merchants Trust Co of Chambersburg PA grew its stake in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. HBC Financial Services PLLC purchased a new stake in Stryker during the 4th quarter valued at $37,000. Bourgeon Capital Management LLC purchased a new position in shares of Stryker in the 4th quarter worth $37,000. Operose Advisors LLC grew its holdings in shares of Stryker by 308.6% in the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after acquiring an additional 108 shares during the period. Finally, Venturi Wealth Management LLC grew its holdings in shares of Stryker by 97.1% in the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after acquiring an additional 67 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on SYK. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a report on Wednesday, January 31st. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and lifted their target price for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Wells Fargo & Company lifted their price objective on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Finally, Evercore ISI increased their target price on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $340.67.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 212,109 shares of company stock worth $72,845,768. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.5 %

Shares of SYK stock traded down $1.54 on Friday, reaching $335.61. 1,042,565 shares of the company’s stock were exchanged, compared to its average volume of 1,284,137. The company’s fifty day simple moving average is $348.88 and its 200 day simple moving average is $314.88. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $127.69 billion, a PE ratio of 40.68, a P/E/G ratio of 2.71 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm’s revenue was up 11.8% compared to the same quarter last year. During the same quarter last year, the firm posted $3.00 EPS. As a group, analysts forecast that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. Stryker’s payout ratio is presently 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.